Avacta Therapeutics
  • About
  • Our Science
  • Pipeline
  • News
  • Investors
  • Careers
  • Contact
  • About
    • About Avacta
    • Leadership
    • Scientific Resources
    • Intellectual Property
  • Our Science
    • Our Science
    • 1st Gen
    • 2nd Gen
    • 3rd Gen
    • Partners
    • Clinical trials
  • Pipeline
  • News
  • Investors
    • Investors
    • Key info
    • Corporate Governance
    • Resources
    • Share price
    • RNS News
    • Events
    • Research
  • Careers
    • Job vacancies
    • Benefits of working at Avacta
  • Contact
  • About
    • About Avacta
    • Leadership
    • Scientific Resources
    • Intellectual Property
  • Our Science
    • Our Science
    • 1st Gen
    • 2nd Gen
    • 3rd Gen
    • Partners
    • Clinical trials
  • Pipeline
  • News
  • Investors
    • Investors
    • Key info
    • Corporate Governance
    • Resources
    • Share price
    • RNS News
    • Events
    • Research
  • Careers
    • Job vacancies
    • Benefits of working at Avacta
  • Contact
Home News Investors Page 2
filter by: view all | Blogs | Diagnostics | Investors | Podcasts and Videos | R&D Spotlights Series | Therapeutics

Investors

26 Mar 2025

Avacta Therapeutics Announces Presentations at 2025 AACR Annual Meeting

Investors | Therapeutics
25 Mar 2025

Avacta Announces Completion of the Sale of Launch Diagnostics

Diagnostics | Investors
14 Mar 2025

Panmure Meet the CEO podcast

Investors | Podcasts and Videos | Therapeutics
10 Mar 2025

Avacta Therapeutics to Present at the 2025 Leerink Global Healthcare Conference

Investors
07 Mar 2025

Avacta Announces Promising Early Efficacy and Safety Data for AVA6000 in the Phase 1a Dose Escalation and Ongoing Enrollment in the Phase 1b Expansion Cohorts

Investors | Therapeutics
07 Mar 2025

Avacta Announces Agreement to Sell Launch Diagnostics and a Corporate Update

Diagnostics | Investors
04 Feb 2025

Appointment of Joint Broker

Investors
21 Jan 2025

Issue of Equity and Total Voting Rights

Investors
16 Jan 2025

Avacta Announces Positive New Data from the AVA6000 Phase 1 trial Demonstrating Clinically Meaningful Tumor Shrinkage in Patients with Salivary Gland Cancers

Investors | Therapeutics
13 Jan 2025

Avacta Appoints Brian Hahn as Chief Financial Officer

Investors | Therapeutics

Posts navigation

Older posts
Newer posts
Avacta Therapeutics
  • Diagnostics
  • Terms of Use
  • Terms & Conditions
  • Privacy Policy
  • Intellectual Property
  • Corporate Responsibility
  • Contact Us

Avacta Group plc

Scale Space,  White City
Imperial College Campus
58 Wood Lane
London
W12 7RZ

+44 (0)20 3911 0353

Investor Enquiries

ICR Consilium
85 Gresham Street
London
EC2V 7NQ

 

Email

Twitter | Linkedin

©2025 Avacta Therapeutics. Registered company no. 06605196.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok